Search

The method of boron neutron capture therapy for malignant tumors, proposed in 1936, is beginning to enter clinical practice. The development of dosimetry tools for characterization of therapeutic mixed neutron-photon beam and assessing the patient’s response to treatment is becoming relevant. In this work, a number of dosimetric techniques have been developed: a compact neutron detector with a pair of cast scintillators, one of which is enriched with boron, to measure the boron dose and the γ-ray dose; cell dosimeter for measuring the sum of the equivalent dose of fast neutrons and the equivalent nitrogen dose; prompt γ-ray spectroscopy for in situ measurement of boron dose in real time; epithermal neutron flux monitor for measuring the epithermal neutron flux. Their verification carried out on the accelerator based neutron source VITA showed that they can become convenient and reliable tools for characterization of neutron beam and assessing the patient’s response to treatment.

In this study, approaches to the synthesis of complex compound of gold with cysteine [AuCys]n for measuring absorbed dose in boron neutron capture therapy (BNCT) were developed. The dependence of the complex particle size on pH were established. Nanocomposite materials based on polylactide containing [AuCys]n particles with an average size of about 20 nm were obtained using the crazing mechanism. The structure of obtained materials was studied by electron microscopy. The release kinetics of [AuCys]n from polymer matrix were investigated. Release of [AuCys]n from the volume of the polymeric matrix had a delayed start—this process began only after 24 h and was characterized by an effective rate constant of 1 μg/h from a 20 mg composite sample. At the same time, in vitro studies showed that the concentration of 6.25 μg/mL was reliably safe and did not reduce the survival of U251 and SW-620 cells.

Hexagonal ferrites with the formula SrxBa(1−x)Fe12O19 (x = 0; 0.3; 0.5; 0.7; and 1) were prepared using the citrate method. The main feature of this synthesis is a relatively low calcination temperature of 700 °C. An X-ray diffraction study revealed a single-phase material. According to SEM, the particles were 50−70 nm in diameter. The Curie temperature of the samples that were determined using the DSC method varied in a very narrow range of 455−459 °C. Analysis of the magnetic hysteresis loops obtained at 300 K and 50 K indicated all samples as magnetically hard materials in a single-domain state. The maximal magnetic characteristics encompass strontium hexaferrite. The terahertz spectra of complex dielectric permittivity and the spectra of infrared reflectivity were measured at room temperature in the range of 6–7000 cm−1. The obtained broad-band spectra of the real and imaginary parts of permittivity reveal significant changes associated with structural distortions of the (Sr,Ba)O12 anti-cuboctahedron caused by the substitution of Ba2+ with Sr2+ in the same crystallographic positions.

We conducted a clinical veterinary study on neutron capture therapy (NCT) at a neutron-producing accelerator with seven incurable pets with spontaneous tumors and gadolinium as a neutron capture agent (gadolinium neutron capture therapy, or GdNCT). Gadolinium-containing dimeglumine gadopentetate, or Gd-DTPA (Magnevist®, 0.6 mL/kg b.w.), was used. We observed mild and reversible toxicity related to the treatment. However, no significant tumor regression in response to the treatment was observed. In most cases, there was continued tumor growth. Overall clinical improvement after treatment was only temporary. The use of Gd-DTPA for NCT had no significant effects on the life expectancy and quality of life of animals with spontaneous tumors. Further experiments using more advanced gadolinium compounds are needed to improve the effect of GdNCT so that it can become an alternative to boron neutron capture therapy. Such studies are also necessary for further NCT implementation in clinical practice as well as in veterinary medicine.

Boron neutron capture therapy (BNCT) is one of the promising treatment methods for malignant melanoma. The main issue of this technology is the insufficient selectivity of 10B accumulation in tumor cells. As a result of the neutron absorption by boron, an 84% energy release occurred within the cell by the nuclear reaction 10B (n, α)7Li, which lead to tumor cell death. The use of lithium instead of boron brings a new unique opportunity—local 100% energy release—since all products of the 6Li (n, α)3H reaction have high linear energy transfer characteristics. The aim of this study was to determine the concentrations of Li in the tumor, skin, blood, brain and kidney in experimental animals with B16 melanoma and to analyze the potential Li toxicity after lithium carbonate administration at single doses of 300 and 400 mg/kg. Lithium carbonate was chosen since there is a long-term experience of its use in clinical practice for the treatment of psychiatric disorders. The inductively coupled plasma atomic emission spectrometry was used to evaluate Li concentrations in tissue samples. The accumulation efficiency of Li in the tumor was the highest at a time point of 30 min (22.4 µg/g; at a dose of 400 mg/kg). Despite the high lithium accumulation in the kidneys, the pathological changes in kidney tissues were not found. Thus, lithium may actually be used for the Li-NCT development and future studies can be conducted using 6Li and following irradiation of tumor cells using the schemes of lithium administration tested in this work.

The Chelyabinsk superbolide, the largest in XXI century, which exploded on 15 February 2013 over snowy fields of Southern Urals was a historic event not just only because of its massive scale and explosive power. High-temperature, high-pressure conditions in the front shock wave caused intense ablation of the asteroid material and formation of huge amount of meteoritic dust dispersed in the atmosphere during the flyby. Massive snowfalls just few days before and after the event conserved precipitated meteoritic dust in thin layer of snow which was collected and studied later. The most intriguing and challenging material discovered in the dust was closed-shell 10–70 µm exotic polygonal graphitic carbon microcrystals of undisclosed nature. Using optical and electron microscopy and Raman spectroscopy the atomic structure of closed-shell microcrystals was thoroughly studied and their graphitic nature was revealed. It was found that some of the particles formed by multilayer graphitic polygonal shells have extensive hollows inside. Comparative microscopic and spectroscopic analysis of meteorite exotic carbon microcrystals with different graphite species, carbon onions, and diamond revealed two distinctively different closed-shell carbon particles. The first type of the particles can be attributed to carbon onions with characteristic graphite nanocrystalline basic structural units (BSU) of 49 nm lateral size and less and, probably, BSU heteroatomic termination necklace with oxygen content comparable to 1.1% and more. It was shown that the second type of unique graphitic carbon particles of a convex shape and perfect hexagonal symmetry with lateral dimensions of 14 µm correspond to multiply twinned closed-shell graphite microcrystals with polyhexacyclooctadecane (–C18–)n core wrapped by multiple layers of carbon honeycombs with low (

Tetrataenite (L10-FeNi) is a promising candidate for use as a permanent magnet free of rare-earth elements because of its favorable properties such as high magnetic anisotropy and coercivity. We report on structural properties of Fe49Ni49Ti2 alloy after severe plastic deformation (SPD) by high pressure torsion (HPT) technique. The main magnetic and structural characteristics of bulk and HPT materials were determined. As a result of plastic deformation, all samples were obtained with high concentration of defects and stressed state. Low-temperature annealing was used to accelerate the kinetics of phase formation and the possible appearance of nuclei of a stable chemically ordered L10 phase of tetrataenite. Our research shows that it is premature to talk about the formation of even a small amount of phase L10. Additional research needs to be done.

Dysprosium possesses the highest magnetic moment among the rare-earth elements and undergoes a second-order magnetic phase transition to a complex helical antiferromagnetic ordering at Néel temperature TN = 180 K which is followed by a transformation to the ferromagnetic ordering at a lower temperature. Superior magnetic properties and tunability of the magnetic phase transition temperatures make Dy and its solid solutions perspective for the use in technology of magnetic refrigeration at cryogenic temperatures, specifically for the liquefaction of natural gases. In this work we report on the evolution of magnetic properties in solid solutions of Dy100-xYx (x = 0 – 15). It was found that the dilution of Dy magnetic subsystem by a non-magnetic Y has rather a weak impact on the magnetization saturation, which decreases from Ms ∼280 A⋅m2/kg in the x = 0 sample to Ms ∼259 A⋅m2/kg in the x = 15 sample. As a consequence, the isothermal magnetic entropy change was found to decrease slightly in the series of Dy100-xYx (x = 0 – 15) solid solutions.

Sufficient boron-10 isotope (10B) accumulation by tumor cells is one of the main requirements for successful boron neutron capture therapy (BNCT). The inability of the clinically registered 10B-containing borophenylalanine (BPA) to maintain a high boron tumor concentration during neutron irradiation after a single injection has been partially solved by its continuous infusion; however, its lack of persistence has driven the development of new compounds that overcome the imperfections of BPA. We propose using elemental boron nanoparticles (eBNPs) synthesized by cascade ultrasonic dispersion and destruction of elemental boron microparticles and stabilized with hydroxyethylcellulose (HEC) as a core component of a novel boron drug for BNCT. These HEC particles are stable in aqueous media and show no apparent influence on U251, U87, and T98G human glioma cell proliferation without neutron beam irradiation. In BNCT experiments, cells incubated with eBNPs or BPA at an equivalent concentration of 40 µg 10B/mL for 24 h or control cells without boron were irradiated at an accelerator-based neutron source with a total fluence of thermal and epithermal neutrons of 2.685, 5.370, or 8.055 × 1012/cm2. The eBNPs significantly reduced colony-forming capacity in all studied cells during BNCT compared to BPA, verified by cell-survival curves fit to the linear-quadratic model and calculated radiobiological parameters, though the effect of both compounds differed depending on the cell line. The results of our study warrant further tumor targeting-oriented modifications of synthesized nanoparticles and subsequent in vivo BNCT experiments.

(1) Background: accelerator-based neutron sources are a new frontier for BNCT but many technical issues remain. We aimed to study such issues and results in larger-animal BNCT (cats and dogs) with naturally occurring, malignant tumors in different locations as an intermediate step in translating current research into clinical practice. (2) Methods: 10 pet cats and dogs with incurable, malignant tumors that had no treatment alternatives were included in this study. A tandem accelerator with vacuum insulation was used as a neutron source. As a boron-containing agent, 10B-enriched sodium borocaptate (BSH) was used at a dose of 100 mg/kg. Animal condition as well as tumor progression/regression were monitored. (3) Results: regression of tumors in response to treatment, improvements in the overall clinical picture, and an increase in the estimated duration and quality of life were observed. Treatment-related toxicity was mild and reversible. (4) Conclusions: our study contributes to preparations for human BNCT clinical trials and suggests utility for veterinary oncology.

(1) Background: Developments in accelerator-based neutron sources moved boron neutron capture therapy (BNCT) to the next phase, where new neutron radiation parameters had to be studied for the treatment of cancers, including brain tumors. We aimed to further improve accelerator-BNCT efficacy by optimizing dosimetry control, beam parameters, and combinations of boronophenylalanine (BPA) and sodium borocaptate (BSH) administration in U87MG xenograft-bearing immunodeficient mice with two different tumor locations. (2) Methods: The study included two sets of experiments. In Experiment #1, BPA only and single or double irradiation in higher doses were used, while, in Experiment #2, BPA and BSH combinations and single or double irradiation with dosage adjustment were analyzed. Mice without treatment or irradiation after BPA or BPA+BSH injection were used as controls. (3) Results: Irradiation parameter adjustment and BPA and BSH combination led to 80–83% tumor-growth inhibition index scores, irradiation:BNCT ratios of 1:2, and increases in animal life expectancy from 9 to 107 days. (4) Conclusions: Adjustments in dosimetry control, calculation of irradiation doses, and combined use of two 10B compounds allowed for BNCT optimization that will be useful in the development of clinical-trial protocols for accelerator-based BNCT.

Boron neutron capture therapy (BNCT) is an anticancer modality realized through 10B accumulation in tumor cells, neutron irradiation of the tumor, and decay of boron atoms with the release of alpha-particles and lithium nuclei that damage tumor cell DNA. As high-LET particle release takes place inside tumor cells absorbed dose calculations are difficult, since no essential extracellular energy is emitted. We placed gold nanoparticles inside tumor cells saturated with boron to more accurately measure the absorbed dose. T98G cells accumulated ~50 nm gold nanoparticles (AuNPs, 50 µg gold/mL) and boron-phenylalanine (BPA, 10, 20, 40 µg boron-10/mL), and were irradiated with a neutron flux of 3 × 108 cm−2s−1. Gamma-rays (411 keV) emitted by AuNPs in the cells were measured by a spectrometer and the absorbed dose was calculated using the formula D = (k × N × n)/m, where D was the absorbed dose (GyE), k—depth-related irradiation coefficient, N—number of activated gold atoms, n—boron concentration (ppm), and m—the mass of gold (g). Cell survival curves were fit to the linear-quadratic (LQ) model. We found no influence from the presence of the AuNPs on BNCT efficiency. Our approach will lead to further development of combined boron and high-Z element-containing compounds, and to further adaptation of isotope scanning for BNCT dosimetry.

A compact accelerator-based neutron source has been proposed and created at the Budker Institute of Nuclear Physics in Novosibirsk, Russia. An original design tandem accelerator is used to provide a proton beam. The neutron flux is generated as a result of the 7Li(p,n)7Be threshold reaction using the solid lithium target. A beam shaping assembly is applied to convert this flux into a beam of epithermal neutrons with characteristics suitable for BNCT. The BNCT technique is being tested in in vitro and in vivo studies, and dosimetry methods are being developed. Currently, the BNCT technique has entered into clinical practice in the world: after successful clinical trials, two clinics in Japan began treating patients, and four more BNCT clinics are ready to start operating. The neutron source proposed at the Budker Institute of Nuclear Physics served as a prototype for a facility created for a clinic in Xiamen (China). It is planned to equip the National Medical Research Center of Oncology (Moscow, Russia) and National Oncological Hadron Therapy Center (Pavia, Italy) with the same neutron sources. Due to the impending use of an accelerator neutron source for treating patients, the validation of the neutron yield of the 7Li(p,n)7Be reaction in lithium metal targets is required. The theoretical neutron yield has not been evaluated experimentally so far.

A compact accelerator-based neutron source has been proposed and created at the Budker Institute of Nuclear Physics in Novosibirsk, Russia. An original design tandem accelerator is used to provide a proton beam. The proton beam energy can be varied within a range of 0.6–2.3 MeV, keeping a high-energy stability of 0.1%. The beam current can also be varied in a wide range (from 0.3 mA to 10 mA) with high current stability (0.4%). In the device, neutron flux is generated as a result of the 7Li(p,n)7Be threshold reaction. A beam-shaping assembly is applied to convert this flux into a beam of epithermal neutrons with characteristics suitable for BNCT. A lot of scientific research has been carried out at the facility, including the study of blistering and its effect on the neutron yield. The BNCT technique is being tested in in vitro and in vivo studies, and the methods of dosimetry are being developed. It is planned to certify the neutron source next year and conduct clinical trials on it. The neutron source served as a prototype for a facility created for a clinic in Xiamen (China).

Fly ash produced during coal combustion is one of the major sources of air and water pollution, but the data on the impact of micrometer-size fly ash particles on human cells is still incomplete. Fly ash samples were collected from several electric power stations in the United States (Rockdale, TX; Dolet Hill, Mansfield, LA; Rockport, IN; Muskogee, OK) and from a metallurgic plant located in the Russian Federation (Chelyabinsk Electro-Metallurgical Works OJSC). The particles were characterized using dynamic light scattering, atomic force, and hyperspectral microscopy. According to chemical composition, the fly ash studied was ferro-alumino-silicate mineral containing substantial quantities of Ca, Mg, and a negligible concentration of K, Na, Mn, and Sr. The toxicity of the fly ash microparticles was assessed in vitro using HeLa cells (human cervical cancer cells) and Jurkat cells (immortalized human T lymphocytes). Incubation of cells with different concentrations of fly ash resulted in a dose-dependent decrease in cell viability for all fly ash variants. The most prominent cytotoxic effect in HeLa cells was produced by the ash particles from Rockdale, while the least was produced by the fly ash from Chelyabinsk. In Jurkat cells, the lowest toxicity was observed for fly ash collected from Rockport, Dolet Hill and Muscogee plants. The fly ash from Rockdale and Chelyabinsk induced DNA damage in HeLa cells, as revealed by the single cell electrophoresis, and disrupted the normal nuclear morphology. The interaction of fly ash microparticles of different origins with cells was visualized using dark-field microscopy and hyperspectral imaging. The size of ash particles appeared to be an important determinant of their toxicity, and the smallest fly ash particles from Chelyabinsk turned out to be the most cytotoxic to Jukart cells and the most genotoxic to HeLa cells.

Direct determinations of the isothermal entropy increment, \(-\Delta S_T\), in the Heusler alloy Ni\(_{50}\)CoMn\(_{36}\)Sn\(_{13}\) on demagnetization gave positive values, corresponding to a normal magnetocaloric effect. These values contradict the results derived from heat-capacity measurements and also previous results obtained from magnetization measurements, which indicated an inverse magnetocaloric effect, but showing different values depending on the technique employed. The puzzle is solved, and the apparent incompatibilities are quantitatively explained considering the hysteresis, the width of the martensitic transition and the detailed protocol followed to obtain each datum. The results show that these factors should be analyzed in detail when dealing with Heusler alloys.

A vacuum-insulated tandem accelerator was used to observe in situ blistering during 2-MeV proton irradiation of metallic samples to a fluence of up to 6.7 × 1020 cm−2. Samples consisting of copper of different purity, tantalum and tantalum-copper compounds were placed on the proton beam path and forced to cool. The surface state of the samples was observed using a charge-coupled device camera with a remote microscope. Thermistors, a pyrometer and an infrared camera were applied to measure the temperature of the samples during irradiation. After irradiation, the samples were analyzed on an X-ray diffractometer, laser and electron microscopes. The present study describes the experiment, presents the results obtained and notes their relevance and significance in the development of a lithium target for an accelerator-based neutron source, for use in boron neutron capture therapy of cancer.